LAUSR

REFERENCES 1. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501-5506. 2. Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282-287. 3. Pulte D, Redaniel MT, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55:1083-1089. 4. Ailawadhi S, Frank RD, Advani P, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEERmedicare analysis. Cancer Med. 2017;6:2876-2885. 5. Ravi G, Chamoun K, Boughan KM, et al. Stem cell transplant minimizes insurance coverage-driven outcomes disparities for multiple myeloma patients. Blood. 2019;134:424. 6. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:12421258. 7. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548. 8. Fillmore NR, Yellapragada SV, Ifeorah C, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133:26152618. 9. Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BCH. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020;10:80. https://doi.org/10.1038/s41408-02000347-6 10. Badar T, Hari P, Dávila O, et al. African Americans with translocation t (11; 14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021;127(1):82-92.